Methods of treatment involving p21/CIP1

a technology of rheumatoid arthritis and p21cip1, which is applied in the field of molecules for suppressing inflammation of rheumatoid arthritis, can solve the problems of little evidence proving that these drugs arrest the progression of the disease, the inability to achieve total prevention of joint destruction through conventional treatments, and the inability to achieve the effect of preventing aberrant growth and/or inflammation of synovial tissue, promoting expression or function of p21cip1 protein, and the inability to

Inactive Publication Date: 2008-09-18
MIYASAKA NOBUYUKI +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The present invention is based on the finding that an anti-inflammatory effect can be obtained by raising the expression of p21Cip1 protein in inflammation synovial tissue. The objective of the present invention is to inhibit aberrant growth and/or inflammation of the synovial tissue by promoting expression or function of p21Cip1 protein. More specifically, the present invention provides p21Cip1 protein

Problems solved by technology

Most patients respond well to these drugs, but some are resistant or the effect of these drugs decreases after a period of disease remission in other patients.
Moreover, there is little evidence proving that these drugs arrest the progression of the disease in the long run.
It is p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treatment involving p21/CIP1
  • Methods of treatment involving p21/CIP1
  • Methods of treatment involving p21/CIP1

Examples

Experimental program
Comparison scheme
Effect test

example 1

Transfection of Adenoviral Vectors Incorporated with p16INK4a and p21Cip1 Gene Inhibits Synovial Cell Proliferation

[0081]The anti-proliferative effects of the forced expression of p21Cip1 as well as p16INK4a on the synovial cells were examined using human synovial fibroblasts. RSFs prepared from the rheumatoid synovial tissues were infected with the recombinant adenoviruses AxCAp16, AxCAp21, or AxCALacZ, containing p16INK4a, p21Cip1, or E. coli lacZ, respectively. Replication-defective adenoviruses containing a human p16INK4a gene and a human p21Cip1 gene (AxCAp16 and AxCAp21, respectively) were kindly supplied by Drs. Terada and Ito (Tokyo Medical and Dental University, Tokyo, Japan) (Terada, Y. et al., 1997, J. Am. Soc. Nephrol. 8: 51-60). A recombinant adenovirus encoding the lacZ gene (AxCALacZ) was kindly provided by Dr. Saito (University of Tokyo, Tokyo, Japan) (Kanegae, Y. et al., 1995, Nucleic Acids Res. 23:3816-3821). High-titer recombinant adenoviruses were prepared by am...

example 2

Effects of p16INK4a and p21Cip1 Gene Induction on the Pathology of CIA

[0083]The same set of adenoviruses as in Example 1 was used to induce the p16INK4a, p21Cip1, or lacZ gene in vivo in the synovial tissues of CIA mice.

[0084]Induction of CIA was performed as follows. Male DBA / 1J mice were purchased from Japan Charles River Laboratories (Tokyo, Japan) and housed in the Tokyo Medical and Dental University Animal Research Center. Bovine type II collagen (Collagen Research Center, Tokyo, Japan) was dissolved at 2 mg / ml in 0.1 M acetic acid, then was emulsified with an equal volume of complete Freund's adjuvant (Iatron, Tokyo, Japan) . A hundred microliter of the immunogen was injected intradermally into 8-weeks-old mice at the tail base. After 3 weeks, the mice received the same antigen subcutaneously. Arthritis was developed within 10 days of the second immunization.

[0085]In vivo gene transfection into the joints was performed either on the same day as the second immunization and 10 d...

example 3

Effects of p16INK4a and p21Cip1 Gene Induction on the Expression of Pro-Inflammatory Cytokines in the CIA-Affected Joints

[0091]As in the case of RA, TNF-α and IL-1, which are mainly secreted from the synovial cells, largely account for the pathology of CIA (Piguet, P. F. et al. , 1992, Immunology 77: 510-514; Williams, R. O. et al. , 1992, Proc. Natl. Acad. Sci. USA. 89: 9784-9788; Wooley, P. H. et al., 1993, J. Immunol. 151: 6602-6607; Joosten, L. A. B. et al., 1996, Arthritis Rheum. 39: 797-809). Thus, the inventors studied the expression of the pro-inflammatory cytokines, IL-1β, IL-6, and TNF-α, in arthritic joints administered with AxCAp16, AxCAp21, AxCALacZ adenovirus, or saline. The synovial tissues from the hind paws were collected on the day of histopathological examination. mRNA expression levels of these cytokines were analyzed by RT-PCR.

[0092]Total RNA was extracted from the arthritic synovial tissues with Isogen (Nippongene Co., Tokyo, Japan) for RT-PCR analysis. cDNA wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16INK4a and p21Cip1 p in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or the expression of inflammatory cytokines in synovial tissues targeting the p21Cip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.

Description

CLAIM OF PRIORITY[0001]This application is a continuation of U.S. patent application Ser. No. 10 / 088,661, filed on Jul. 19, 2002, which is the U.S. National Phase of International Patent Application No. PCT / JP00 / 06511, filed on Sep. 22, 2000, which claims the benefit of Japanese Patent Application No. 11-269579, filed on Sep. 22, 1999. The entire contents of each of the foregoing applications are hereby incorporated by reference.TECHNICAL FIELD[0002]The present invention relates to molecules for suppressing inflammation of Rheumatoid arthritis (RA) and the screening of those molecules.BACKGROUND ART[0003]Rheumatoid arthritis (RA) is characterized by the synovial inflammation of multiple joints. The affected synovial tissues contain activated macrophages, fibroblasts, T- and B-lymphocytes. The synovial fibroblasts proliferate and release tissue-degrading enzymes in response to pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6, which are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/76A61K38/00G01N33/00C12Q1/68A61P19/00A01K67/027C12Q1/02A61K31/70A61K38/17A61K48/00A61P19/02A61P29/00A61P43/00C12N15/12C12Q1/6897G01N33/68
CPCA61K38/005A61K38/1709A61K48/00C12Q1/6897G01N2500/04G01N33/6863G01N2333/4739G01N2500/00G01N33/68A61P19/00A61P19/02A61P29/00A61P43/00
Inventor MIYASAKA, NOBUYUKIKOHSAKA, HITOSHI
Owner MIYASAKA NOBUYUKI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap